New Line Cinema is operating at peak commercial form in 2025, with four horror releases combining for $768 million worldwide and a pipeline of franchise sequels and co-productions extending into 2026.
Each signal is one documented data point captured by our continuous pipeline: a trade-press mention, festival market activity, executive statement, or acquisition activity update. Higher signal volume means New Line Cinema is generating more public market activity right now.
"New Line is an essential partner. Their ability to tap into the zeitgeist more than anyone is extraordinary. They have the special sauce and they understand horror." — Jeff Goldstein, Warner Bros. distribution chief
New Line Cinema is currently riding the strongest horror cycle in its recent history. Four horror titles released in 2025, including "Companion," "Final Destination: Bloodlines," "Weapons," and "The Conjuring: Last Rites," have combined for $768 million worldwide, accounting for roughly 20% of Warner Bros.' $3.7 billion global box office since January. "The Conjuring: Last Rites" opened to $84 million domestic and $194 million global, placing New Line alongside its own "It" (2017) and "It: Chapter Two" in the top three highest horror openings in box office history. "Weapons" grossed $251.5 million worldwide after five weekends against a reported $38 million all-in budget.
Over the past 12 months, New Line has demonstrated a consistent pattern of franchise stewardship, IP extension, and strategic co-production. The label has leaned into recurring theatrical windows, notably early September and the Labor Day weekend, as a launchpad for horror targeting teens and young adults. Marketing has been differentiated by project type: mystery-driven campaigns for originals like "Weapons," final-chapter positioning for "The Conjuring: Last Rites," and nostalgia-plus-viral stunts for "Final Destination: Bloodlines." Co-production partnerships with Blumhouse and Atomic Monster have been central to the slate, and Peter Safran's track record building the Conjuring cinematic universe through New Line was cited as a key credential in his appointment to oversee DC Studios alongside James Gunn.
Filmmakers and producers seeking access to New Line should approach through established genre producers with existing studio relationships, particularly those connected to the horror, franchise, or IP-extension space. New Line's upcoming slate, including "Mortal Kombat II" (May 2026), "Evil Dead Burn," and Lee Cronin's "The Mummy" (co-produced with Blumhouse and Atomic Monster), signals continued appetite for franchise sequels and co-produced genre projects rather than unsolicited spec material.
"New Line is an essential partner. Their ability to tap into the zeitgeist more than anyone is extraordinary. They have the special sauce and they understand horror." — Jeff Goldstein, Warner Bros. distribution chief
Major studios investing in live-action/animated hybrid formats using globally recognized brand IP with proven international market appeal.
This page is a public snapshot of New Line Cinema, kept fresh from trade-press signals. ScriptMatch is the live market-data engine behind it. Upload your script, and we use the same continuously-indexed buyer activity to tell you which production companies and distributors are actively acquiring projects like yours right now, why each one fits, and exactly how to reach them.
New Line Cinema does not have a publicized open-submission policy and operates as a major studio label under Warner Bros. Access is typically brokered through established producers, agents, or entertainment attorneys with existing studio relationships. The label's recent acquisitions, including 'Companion' and 'Weapons,' were brought in through producer and industry channels rather than open calls. Writers without representation should secure a producing partner with a track record in genre film before approaching.
New Line's recent slate spans a notable range. 'Weapons' carried a reported $38 million all-in budget and grossed $251.5 million worldwide, reflecting the label's appetite for mid-budget genre films with strong returns. At the higher end, Warner Bros. studio chiefs are reportedly pushing $100 million auteur-driven originals through the broader WB/New Line pipeline. Co-productions with partners like Blumhouse and Atomic Monster suggest New Line also pursues cost-sharing structures for genre projects.
Festival acquisition is not prominently documented in New Line's recent activity. The label's current slate is built around franchise sequels ('Mortal Kombat II,' 'Final Destination: Bloodlines'), IP extensions ('The Mummy,' 'Evil Dead Burn'), and co-productions with genre specialists like Blumhouse and Atomic Monster. That said, genre-focused festivals remain a viable discovery channel for producers seeking to attach a project before bringing it to a major label like New Line.
New Line has 53 decision makers tracked across recent industry signals, according to available data. The most documented pathway is through established genre producers with existing Warner Bros. or New Line relationships. Peter Safran's producing history with New Line on the Conjuring universe is a cited example of how long-term producer partnerships shape the label's slate. Industry events, WGA-signatory agencies, and entertainment law firms with WB relationships are the practical access points for new voices.
Horror is unambiguously New Line's primary focus in the current cycle. The label released four horror films in 2025 ('Companion,' 'Final Destination: Bloodlines,' 'Weapons,' 'The Conjuring: Last Rites') combining for $768 million worldwide. Jeff Goldstein, Warner Bros. distribution chief, has publicly stated New Line 'understands horror' and has 'the special sauce.' The upcoming pipeline adds franchise action ('Mortal Kombat II') and horror-adjacent IP ('The Mummy,' 'Evil Dead Burn'), reinforcing genre as the label's commercial core.
New Line's 30-day and 90-day unique deal counts currently read at zero in tracked data, though deal velocity registers at 1 in the 30-day window. The label's most recent documented acquisitions, 'Companion' and 'Weapons,' were completed in early 2023. With a packed 2025 release slate and a 2026 pipeline already dated ('Mortal Kombat II,' May 2026), New Line appears to be in a release-and-marketing phase rather than an active acquisition sprint, though co-production opportunities with partners like Blumhouse and Atomic Monster remain ongoing.
Profile compiled from publicly-available sources: trade press (Deadline, Variety, IndieWire, The Hollywood Reporter, Screen Daily), festival market reports (Cannes Marche, AFM, EFM, TIFF Industry), executive public statements, and acquisition announcements. Activity counters reflect signal volume from continuous pipeline indexing.
See an inaccuracy? Suggest a correction. Profiles update continuously as new public information becomes available.